The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sequential therapy with the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas: An Adult Brain Tumor Consortium phase I study (ABTC1101).
Matthias Holdhoff
No relevant relationships to disclose
Stuart A. Grossman
Consultant or Advisory Role - Tau Therapeutics (U)
Jeffrey G. Supko
Research Funding - Tau Therapeutics
Xiaobu Ye
No relevant relationships to disclose
Joy D. Fisher
No relevant relationships to disclose
Serena Desideri
No relevant relationships to disclose
Richard L. Wahl
No relevant relationships to disclose
David Schiff
Consultant or Advisory Role - Tau Therapeutics (U)